title: Nanoparticle Targeting CD44-Positive Cancer Cells for Site-Specific Drug Delivery in Prostate Cancer Therapy.
abstract: Prostate cancer is one of the leading causes of cancer death in adult men and is a multistage disease with therapeutic challenges of local recurrent advanced tumors and distant metastatic disease. CD44 is a multifunctional and multistructural cell surface glycoprotein that is involved in cell-cell interactions, cell proliferation, and cell migration. In the study, we produced negatively charged and biocompatible hyaluronic acid-based nanoparticles as a therapeutic system for targeting CD44-positive cancer cells. Subsequently, we confirmed the delivery of bioactive epigallocatechin-3-gallate and site-specific inhibition of prostate tumor growth. In this study, hyaluronic acid-based nanoparticles successfully encapsulated epigallocatechin-3-gallate and were efficiently internalized into cancer cells via CD44 ligand receptor recognition, induced cell cycle arrest at G2/M phase, and inhibited prostate cancer cell growth. Furthermore, in vivo assays indicated that these nanoparticles specifically bind CD44 receptors and increase apoptosis of cancer cells, leading to significant decreases in prostate tumor activity and tumor tissue inflammation.
authors: Department of Applied Cosmetology, Master Program of Cosmetic Science, Hung-Kuang University , Taichung 43302, Taiwan.
authors: Wen-Ying
authors: WY
authors: Huang
authors: Department of Biological Science and Technology, China Medical University , Taichung 40402, Taiwan.
authors: Jia-Ni
authors: JN
authors: Lin
authors: Department of Urology, University of Texas Southwestern Medical Center , Dallas, Texas 75390, United States.
authors: Jer-Tsong
authors: JT
authors: Hsieh
authors: Department of Biological Science and Technology, China Medical University , Taichung 40402, Taiwan.
authors: Shen-Chieh
authors: SC
authors: Chou
authors: Department of Microbiology and Immunology, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University , Taoyuan 33302, Taiwan.
authors: Chih-Ho
authors: CH
authors: Lai
authors: Department of Urology, University of Texas Southwestern Medical Center , Dallas, Texas 75390, United States.
authors: Eun-Jin
authors: EJ
authors: Yun
authors: Department of Urology, University of Texas Southwestern Medical Center , Dallas, Texas 75390, United States.
authors: U-Ging
authors: UG
authors: Lo
authors: Department of Urology, University of Texas Southwestern Medical Center , Dallas, Texas 75390, United States.
authors: Rey-Chen
authors: RC
authors: Pong
authors: Bio-medical Carbon Technology Co., Ltd , Taichung 40852, Taiwan.
authors: Jui-Hsiang
authors: JH
authors: Lin
authors: Department of Biological Science and Technology, China Medical University , Taichung 40402, Taiwan.|Department of Urology, University of Texas Southwestern Medical Center , Dallas, Texas 75390, United States.
authors: Yu-Hsin
authors: YH
authors: Lin
mesh_terms: D045744:Cell Line, Tumor; D016503:Drug Delivery Systems; D006801:Humans; D018960:Hyaluronan Receptors; D006820:Hyaluronic Acid; D008297:Male; D053758:Nanoparticles; D011471:Prostatic Neoplasms
chemical_list: C497483:CD44 protein, human; D018960:Hyaluronan Receptors; D006820:Hyaluronic Acid
keywords: CD44; epigallocatechin-3-gallate; hyaluronic acid; nanoparticles; prostate cancer